Varda pursues drug manufacturing in orbit

Varda Space Industries is trying to turn orbital flight into a drug-manufacturing service. The El Segundo, California, company said on May 13 that it had signed a research collaboration with United Therapeutics to process small-molecule medicines for rare pulmonary disease aboard multiple missions to low Earth orbit. The pitch is specific: make and crystallize compounds in microgravity, bring them back to Earth, and test whether the resulting forms have properties that are hard to achieve in terrestrial manufacturing. (prnewswire.com) Scientific American reported this week that Varda’s effort is emerging as one of the clearest commercial tests of whether in-orbit manufacturing can expand the space business beyond launch, satellites and communications. (varda.com) ### What exactly did Varda announce on May 13? Varda said on May 13 that it would work with United Therapeutics Corporation on microgravity-based drug formulation for treatments aimed at rare pulmonary disease. The companies said they plan to process compounds aboard Varda’s orbital manufacturing and reentry platform during multiple missions to low Earth orbit. United Therapeutics Chair and CEO Martine Rothblatt said the collaboration would let the company examine whether space-based manufacturing can improve treatments for rare pulmonary disease. Varda CEO Will Bruey said the company wants to connect “microgravity science” to “patient benefit on Earth,” according to the announcement. (prnewswire.com) ### Why does Varda say space changes the drug itself? Varda’s biopharma materials say microgravity suppresses convection, buoyancy and sedimentation, conditions the company says can produce crystals that are more uniform in size and structure. The company says those effects can be locked into the material in orbit and then studied on Earth for possible gains in shelf life, bioavailability and delivery. (prnewswire.com) The May 13 announcement made the same case in more concrete terms. Varda and United Therapeutics said microgravity can alter the structure and crystallization properties of therapeutic compounds, with the goal of finding formulations that may improve stability, bioavailability and delivery characteristics. Bruey said microgravity offers “a fundamentally different environment” for manufacturing pharmaceuticals. (prnewswire.com) ### What has Varda actually flown so far? Varda’s platform page says the company has launched and recovered a series of W-class missions built around orbital processing and reentry. The company lists W-1 reentering on Feb. 21, 2024, W-2 on Feb. 27, 2025, W-3 on May 13, 2025, W-4 launching on June 23, 2025, W-5 reentering, and W-6 as its first launch of 2026. (varda.com) The W-4 mission description says that flight was the first to use a Varda-built satellite bus and included solution-based pharmaceutical processing. Varda also said W-4 was covered by Federal Aviation Administration permission to reenter capsules through 2029 under a Part 450 vehicle operator license. ### Is there evidence the company has already produced a drug-related result? Improved Pharma, a Varda collaborator, said its first joint research project with the company was published in 2022 and reported a new form of ritonavir. (prnewswire.com) A May 5 release from Improved Pharma said a recent paper described the chemical and physical stability of Ritonavir Form III generated in orbit, and said the material remained in that metastable form after exposure to temperature changes, vibration, radiation and acceleration. (varda.com) Bloomberg reported on May 13 that Bruey described Varda’s ritonavir work as an early proof point and said the company planned to expand beyond that result. Scientific American separately reported that the company is now trying to move from demonstration flights toward commercial pharmaceutical work. (varda.com) ### What would have to exist for this to become a business, not just an experiment? Scientific American reported that a successful orbital drug program would require more than launch capacity. The magazine said the model depends on payload integration, mission operations, material processing in orbit, reentry and post-flight analysis being packaged into a service that life-science customers can buy. (improvedpharma.com) Varda’s own platform materials describe that same chain as a product. The company says it launches capsules on commercial rockets, processes materials in orbit, separates the capsule from its satellite bus, and returns payloads to Earth by parachute for recovery and analysis. ### What comes next on the record? The May 13 collaboration announcement said the first compounds flown under the United Therapeutics agreement will likely focus on therapies for patients with life-threatening pulmonary diseases. (bloomberg.com) Varda did not name a launch date for those payloads, but said the work would take place across multiple future missions to low Earth orbit. Varda’s mission page says W-6 has already launched as the company’s first mission of 2026, and its platform page says the company is pursuing frequent reentry flights to support continued research and commercial work. (scientificamerican.com) United Therapeutics and Varda will next have to identify the compounds that will fly on those future spacecraft missions. (prnewswire.com) (varda.com)